20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Cobiprostone: Development discontinued

Sucampo discontinued development of cobiprostone following a pre-specified futility analysis of a double-blind, U.S. Phase IIa trial evaluating an oral spray formulation of cobiprostone in about 180 patients undergoing radiochemotherapy for head and neck cancer...
01:01 , Jul 12, 2016 |  BC Extra  |  Clinical News

Sucampo ending cobiprostone development

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) said it will discontinue development of cobiprostone ( SPI-8811) following a futility analysis of a Phase IIa study to prevent oral mucositis in head and neck cancer patients. Sucampo said the...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Cobiprostone: Phase IIa discontinued

Sucampo discontinue development of cobiprostone to treat PPI-refractory NERD or sGERD after top-line data from a double-blind Phase IIa trial in 153 patients with PPI-refractory NERD or sGERD showed that thrice-daily cobiprostone for 8 weeks...
01:00 , Apr 20, 2016 |  BC Extra  |  Clinical News

Sucampo's cobiprostone misses Phase IIa reflux endpoint

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) said it will discontinue development of cobiprostone ( SPI-8811) to treat proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD) after the compound missed the primary...
07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

Cobiprostone regulatory update

FDA granted Fast Track designation to cobiprostone from Sucampo to treat and prevent oral mucositis (OM). The company said it plans to begin a Phase II trial of the prostone chloride channel 2 (...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

Unoprostone isopropyl: Phase III data

Top-line data from a double-blind, Japanese Phase III trial in about 180 patients showed that 0.15% unoprostone isopropyl eye drops missed the primary endpoint of improving mean retinal sensitivity at 4 central points from baseline...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

Amitiza lubiprostone: Phase III started

Sucampo and Takeda began a double-blind, placebo-controlled, international Phase III trial to evaluate 12 or 24 µg oral lubiprostone twice daily for 12 weeks in >500 patients ages 6-17 years with functional constipation. The companies'...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Unoprostone isopropyl: Completed Phase III enrollment

Sucampo said R-Tech Ueno completed enrollment of 180 patients in a double-blind, placebo-controlled, Japanese Phase III trial evaluating 0.15% unoprostone isopropyl eye drops for 52 weeks. The trial includes a 52-week open-label study following the...